Press Release MiNK Therapeutics Reports Second Quarter 2026 Financial Results and Reports Observations from Randomized Phase 2 Trial of agenT-797 in Acute Lung Injury 17 hours ago
Press Release MiNK Therapeutics Presents Early Observations from Ongoing Phase 2 Trial at the 2026 Military Health System Research Symposium Aug 6
Press Release MiNK Therapeutics to Report Second Quarter 2026 Financial Results, Provide Clinical Updates on agenT-797 in Lung Injury, and Highlight Important Business Updates Aug 6